160162-42-5
160162-42-5 結(jié)構(gòu)式
基本信息
RQANARBNMTXCDM-DKOHIBGUSA-N
(E,E,Z,E)-3-Methyl-7-(4-methylphenyl)-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoicacid
2,4,6,8-Nonatetraenoic acid, 3-methyl-7-(4-methylphenyl)-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (2E,4E,6Z,8E)-
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-15870 | SR 11302 | 160162-42-5 | 1 mg | 990元 |
| 2026/06/05 | HY-15870 | SR 11302 SR 11302 | 160162-42-5 | 5mg | 1800元 |
| 2026/06/05 | HY-15870 | SR 11302 SR 11302 | 160162-42-5 | 10mM * 1mLin DMSO | 1980元 |
常見(jiàn)問(wèn)題列表
AP-1
SR 11302 (SR11302) show strong anti-AP-1 activity with selective binding with RARα and RARγ, but not with RARβ and RXRα.
SR 11302 (SR-11302; 1 μM) inhibits AP-1 transcription factor activity and decreases aldosterone levels by 61.9% in hypoxia-treated cells.
SR 11302 (SR-11302; 2 μM; 48 hours) inhibits
Helicobacter pylori
(
H. pylori
)-induced cell proliferation in adenocarcinoma gastric (AGS) cells.
SR 11302 (2 μM; 24 hours) inhibits
H. pylori
-induced expression of β-catenin and c-myc in AGS cells.
SR 11302 (SR11302; low dose 0.5 mg/kg and high dose 1 mg/kg body weight; orally gavaged daily) treatment reduces the total vascular lesion number and lesion size in Vldlr -/- mice in a dose-dependent manner.
| Animal Model: | Vldlr -/- mice |
| Dosage: | Low dose 0.5 mg/kg and high dose 1 mg/kg body weight |
| Administration: | Orally gavaged daily from P5 to P15 |
| Result: | High-dose from P5 to P15 reduced the total vascular lesion number by 48% and decreased the lesion size by 40%, without detectable signs of toxicity in mice, including no change in body weight. |